On November 11, 2023 Saturday, Novo Nordisk presented its data at the American Heart Association annual scientific meeting and published its data in the New England Journal of Medicine saying that the heart protective benefits of its widely popular Wegovy obesity treatment are due to more than weight loss alone. In August, 2023, Novo released early data in this trial called select which showed Wegovy reduced incidents of heart attack stroke or death from heart disease by 20% and help patient lose an average of 15% of their weight. According to this closely watched study that involved 17,600 patients with pre-existing heart disease but not diabetes and lasted nearly 3 years, Wegovy can reduce the risk of a non-fatal heart attack by 28% and heart rate death by 15% compared to a placebo. 

      According to Brand Value (China) Network, Novo Nordisk reported a strong third-quarter sales growth, fueled by Wegovy, Novo Nordisk’s most popular weight-loss drug. Wegovy generated $1.7 billion in quarterly revenue for Novo Nordisk. This strong demand has persisted despite Wegovy facing manufacturing constraints, limited insurer coverage, and low reimbursement from government and employer plans. The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week and has not demonstrated an effect on cardiovascular outcomes.  

    Wegovy is an injectable prescription medication for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems, to help them lose weight and keep it off. Wegovy should be used with a reduced-calorie meal plan and increased physical activity. In 2021, Wegovy was approved by the U.S. Food and Drug Administration (FDA) for long-term weight management. 

     Novo Nordisk is a danish leading global healthcare company, founded in 1923 and headquartered in Denmark. The mission of Novo Nordisk is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. Its main product is the drug semaglutide, used to treat diabetes under the brand name Ozempic and obesity under the brand name Wegovy. As of today, it employes more than 59,000 people in 80 offices around the world and market its products in 170 countries. 

     On the ranking of “The 3rd Daguan·Keweiwei World Brand Value Top 900 ” released on March 18, 2023, Novo Nordisk’s brand value was 672.505 billion RMB, ranking the 23th. Eli Lilly and Company‘s brand value was 119.174 billion RMB, ranking the 220th.

www.bvrcn.com 品牌价值网

        "(www.bvrcn. com) Daguan · Brand Value (China) Network" is a preferred world-class website for spreading global brand news and promoting brand information value. This website continuously tracks and reports the current global brand industry, timely releases brand dynamics, brand information, brand analysis, etc., and promote brand value by using its own resources from multiple perspectives. This website has a strong media presence with over 1000 domestic, international mainstream, and top industry media that can effectively share, reprint news. 

作者：杨瑞安